Filing Details

Accession Number:
0001209191-20-038339
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-06-22 21:17:56
Reporting Period:
2020-06-22
Accepted Time:
2020-06-22 21:17:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
873303 Sarepta Therapeutics Inc. SRPT Pharmaceutical Preparations (2834) 930797222
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1529297 T David Howton 215 First Street, Suite 415
Cambridge MA 02142
Evp, General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-06-22 1,280 $13.71 33,151 No 4 M Direct
Common Stock Acquisiton 2020-06-22 1,858 $13.71 35,009 No 4 M Direct
Common Stock Acquisiton 2020-06-22 56,984 $23.85 91,993 No 4 M Direct
Common Stock Acquisiton 2020-06-22 45,000 $29.03 136,993 No 4 M Direct
Common Stock Disposition 2020-06-22 6,009 $168.61 130,984 No 4 S Direct
Common Stock Disposition 2020-06-22 8,086 $169.56 122,898 No 4 S Direct
Common Stock Disposition 2020-06-22 35,757 $170.59 87,141 No 4 S Direct
Common Stock Disposition 2020-06-22 55,270 $171.50 31,871 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2020-06-22 1,280 $0.00 1,280 $13.71
Common Stock Stock option (right to buy) Disposition 2020-06-22 1,858 $0.00 1,858 $13.71
Common Stock Stock option (right to buy) Disposition 2020-06-22 56,984 $0.00 56,984 $23.85
Common Stock Stock option (right to buy) Disposition 2020-06-22 45,000 $0.00 45,000 $29.03
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2017-02-28 2026-02-28 No 4 M Direct
0 2017-02-28 2026-02-28 No 4 M Direct
0 2013-11-05 2022-11-05 No 4 M Direct
7,708 2015-02-28 2024-02-28 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.
  2. The shares were sold in transactions at prices ranging from $168.04 to $169.0399, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  3. The shares were sold in transactions at prices ranging from $169.09 to $170.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  4. The shares were sold in transactions at prices ranging from $170.09 to $171.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  5. The shares were sold in transactions at prices ranging from $171.09 to $172.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.